Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DuoVitality: Neoadjuvant Tislelizumab + Chemo in EGFR+ NSCLC
NCT05527808Phase 2Recruiting
- Start
- Aug 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in lung adenocarcinoma. Started Aug 2022; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT05527808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05527808.